AbbVie is a US-based pharmaceutical company founded in 2013 through separation from Abbott Laboratories, headquartered in North Chicago.
Is this your business? Add your evidence →
AbbVie has achieved meaningful absolute emissions reductions and maintains science-aligned near-term climate targets, but obscures its full supply chain footprint and lacks net-zero validation. Membership in climate-oppositional trade associations without alignment review, combined with $7.57B in regulatory penalties since 2000, signals weak governance despite robust operational disclosures.
AbbVie scores 48/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified May 2026.
That places AbbVie joint 198th of 847 companies scored, and joint 8th of 19 in Healthcare / Pharmaceuticals.
Where AbbVie sits among healthcare / pharmaceuticals peers.
Among the 19 major healthcare / pharmaceuticals brands we've scored, AbbVie is tied =8th of 19, with 1 other.
Its three lowest-scoring questions, and what the evidence didn't show.
World Benchmarking Alliance notes no soil health, agrobiodiversity, or deforestation disclosures.
No total Scope 3 figure publicly disclosed.
No alignment assessment conducted.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Targets & Commitments (7/10, 7/10). Weakest on Nature & Biodiversity Impact and Carbon Footprint — Supply Chain (3/10, 4/10).
The 3 companies in the sector scoring nearest above AbbVie.
Novartis demonstrates solid operational decarbonization and supply-chain engagement but relies heavily on carbon credits for claimed neutrality.
See the breakdown →Sanofi has delivered genuine absolute emission reductions (47% Scope 1&2, 10% Scope 3 vs 2019) and SBTi-validated net-zero targets to 2045.
See the breakdown →Roche has achieved strong operational decarbonisation (46% S1&2 reduction since 2022) and received SBTi validation for net-zero targets — a pharma first.
See the breakdown →The formula and all 11 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale11 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
AbbVie is a US-based pharmaceutical company founded in 2013 through separation from Abbott Laboratories, headquartered in North Chicago. With $58B in FY2022 revenue, it develops treatments across immunology, oncology, virology, and neuroscience. AbbVie operates a global manufacturing and R&D footprint with complex supply chains typical of large-scale pharma.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.